Published in Cancer on April 01, 2003
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol (2014) 2.23
Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer (2013) 2.13
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem (2008) 1.87
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol (2013) 1.50
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer (2008) 1.45
Renal cell carcinoma. BMJ (2014) 1.45
Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol (2014) 1.44
The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma. Can J Urol (2016) 1.41
Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One (2012) 1.41
Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol (2006) 1.41
Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol (2013) 1.19
Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer (2008) 1.16
Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer (2011) 1.01
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology (2008) 0.93
Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol (2016) 0.91
Metachronous bladder metastases from renal cell carcinoma: a case report and review of the literature. Ecancermedicalscience (2010) 0.90
Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer (2012) 0.90
Expression of endothelin 2 and localized clear cell renal cell carcinoma. Hum Pathol (2011) 0.89
Risk stratification and prognostication of renal cell carcinoma. World J Urol (2008) 0.89
Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma. Biomed Res Int (2015) 0.87
Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma. Can Urol Assoc J (2014) 0.87
Key clinical issues in renal cancer: a challenge for proteomics. World J Urol (2007) 0.87
Staging of renal cell carcinoma: Current concepts. Indian J Urol (2009) 0.86
MRI phenotype in renal cancer: is it clinically relevant? Top Magn Reson Imaging (2014) 0.86
Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients. World J Urol (2016) 0.86
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer (2012) 0.85
The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World J Urol (2014) 0.85
A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol (2016) 0.85
Decision curve analysis and external validation of the postoperative Karakiewicz nomogram for renal cell carcinoma based on a large single-center study cohort. World J Urol (2014) 0.84
Multiple metastatic deposits in the head and neck region from a renal cell carcinoma. Malays J Med Sci (2010) 0.83
Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer (2009) 0.82
The current role of lymph node dissection in the management of renal cell carcinoma. Int J Surg Oncol (2011) 0.81
Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma. Oncotarget (2016) 0.81
Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol (2011) 0.80
Concurrent RCC with tuberculous para-aortic lymphadenopathy: A pleasant surprise. Can Urol Assoc J (2015) 0.80
R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy. Int J Clin Oncol (2015) 0.79
Prognostic factors of overall survival in renal cancer patients - single oncological center study. Cent European J Urol (2013) 0.79
Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol (2012) 0.79
Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma. BMC Cancer (2015) 0.79
Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma. J Urol (2013) 0.79
Mechanisms of coagulative necrosis in malignant epithelial tumors (Review). Oncol Lett (2014) 0.79
Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review. Oncol Lett (2011) 0.79
Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol (2015) 0.78
Systemic adjuvant therapies in renal cell carcinoma. Oncol Rev (2012) 0.78
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging (2015) 0.78
Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. BMC Res Notes (2014) 0.78
Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients? Onco Targets Ther (2014) 0.78
Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma. Oncotarget (2015) 0.78
Chest X-ray in the follow-up of renal cell carcinoma. World J Urol (2013) 0.77
Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. Br J Cancer (2015) 0.77
Preoperative Erythrocyte Sedimentation Rate Independently Predicts Overall Survival in Localized Renal Cell Carcinoma following Radical Nephrectomy. Int J Surg Oncol (2012) 0.77
The role of lymphadenectomy in the management of renal cell carcinoma. World J Urol (2014) 0.77
MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer (2016) 0.76
Medical treatment of renal cancer: new horizons. Br J Cancer (2016) 0.76
High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget (2016) 0.76
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J (2011) 0.76
Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. BMC Cancer (2017) 0.75
ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med (2016) 0.75
Podoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma. Cancer Sci (2016) 0.75
High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. Oncotarget (2016) 0.75
Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Transl Oncol (2016) 0.75
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer (2013) 0.75
A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma. Oncotarget (2016) 0.75
High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. Oncotarget (2016) 0.75
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc (2015) 0.75
Reclassification of the Fuhrman grading system in renal cell carcinoma-does it make a difference? Springerplus (2013) 0.75
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma. Oncotarget (2016) 0.75
Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients. Oncotarget (2016) 0.75
Locally advanced renal cell carcinoma. Can Urol Assoc J (2007) 0.75
Gallbladder's clear cell renal carcinoma metastasis: A case report. Int J Surg Case Rep (2015) 0.75
Comparison of guideline recommendations with daily practice in patients with renal cell carcinoma. Eur J Med Res (2010) 0.75
Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC. Nat Rev Urol (2015) 0.75
Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer. Oncotarget (2016) 0.75
Multiple metastases of renal clear cell carcinoma to the organs of the head. Contemp Oncol (Pozn) (2014) 0.75
Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH. Br J Cancer (2014) 0.75
Prognostic relevance of extensive necrosis in renal cell carcinoma. J Clin Pathol (2005) 0.75
Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? Cancer Res Treat (2014) 0.75
Renal cell cancer: what can we learn from pre-operative studies? Front Oncol (2011) 0.75
Metastatic clear cell variant of renal cell carcinoma of the mandible: Review and case report. Ann Maxillofac Surg (2016) 0.75
Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma. Sci Rep (2016) 0.75
Decreased expression of JMJD3 predicts poor prognosis of patients with clear cell renal cell carcinoma. Oncol Lett (2017) 0.75
High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. Oncotarget (2017) 0.75
The association between renal sinus fat area and the progression-free survival in Chinese non-metastatic clear-cell renal cell carcinoma patients. Oncotarget (2017) 0.75
[Renal cancer biomarkers. What is justified?]. Pathologe (2012) 0.75
Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology (2009) 9.51
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA (2005) 5.52
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
Cognitive and behavioral outcomes after early exposure to anesthesia and surgery. Pediatrics (2011) 3.76
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17
Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol (2004) 3.11
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol (2006) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Increased risk of serious pneumococcal disease in patients with asthma. J Allergy Clin Immunol (2008) 2.97
Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91
Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res (2007) 2.77
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol (2012) 2.70
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med (2002) 2.51
The learning curve of robotic hysterectomy. Obstet Gynecol (2013) 2.47
Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol (2010) 2.45
Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res (2005) 2.42
Pediatric dermoid cysts of the head and neck. Otolaryngol Head Neck Surg (2005) 2.40
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol (2008) 2.40
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36